Department of Medical Genetics and Rare Orthopedic Diseases and CLIBI Laboratory, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Ipsen, Newton, MA, USA.
Bone. 2020 Oct;139:115499. doi: 10.1016/j.bone.2020.115499. Epub 2020 Jun 24.
Multiple osteochondromas is a rare hereditary skeletal disorder, characterized by bony protrusions arising from growth plates on long bones during skeletal development. The disorder frequently leads to diminished stature, deformities and functional limitations. Understanding of the natural history of multiple osteochondromas and its evolution in children and adolescents is limited.
To provide valuable information on the natural history of multiple osteochondromas, to inform recommendations for treatment and prevent impairments caused by osteochondromas.
This retrospective cohort study in children with multiple osteochondromas includes longitudinal data collected from first to last follow-up visit for patient demographics, and over 36 months for disease evolution.
Data were collected from the Registry of Multiple Osteochondromas, which includes data from circa 1200 patients with multiple osteochondromas treated from 2003 to 2017 at IRCCS Istituto Ortopedico Rizzoli in Bologna.
Patients ≤18 years with multiple osteochondromas, who provided written informed consent and had data for ≥1 12-month follow-up visit.
MAIN OUTCOME(S) AND MEASUREMENT(S): Demographics, clinical features, incidence of surgeries, and disease evolution (progression or regression) were assessed. Results were summarized using descriptive statistics, annual rates of new clinical features and surgeries, and Kaplan-Meier estimates. Patient height was evaluated following Italian growth charts.
158 patients were included in these analyses. Throughout follow-up, 80.4% of patients developed new osteochondromas, 57.6% developed new deformities, 23.4% developed new functional limitation(s). New osteochondroma(s) were developed by 28.5% patients by Month 12, 39.9% at Month 24, 50% at Month 36. Most new osteochondromas were detected in the younger population; patients aged 0-4 years underwent a significantly higher number of lesions within 12, 24 and 36 months of follow-up. The overall incidence of patients with ≥1 new deformity within 12 months was 17.7%, with incidences decreasing with increasing age (p = .023). In addition, the analyses on height highlight that 13 years is a cut off age for slow growth of the stature (p < .0005). At last follow-up visit, 46.2% of patients had disease progression, while regression (spontaneous and surgical) occurred in 7.6% (p = .007).
This natural history study reports the main set of clinically relevant data for patients with multiple osteochondromas during skeletal development, providing insight for patient management and development of therapeutic interventions.
重要性:多发性骨软骨瘤是一种罕见的遗传性骨骼疾病,其特征是在骨骼发育过程中长骨的生长板上出现骨突起。该疾病常导致身材矮小、畸形和功能受限。目前对多发性骨软骨瘤的自然史及其在儿童和青少年中的演变了解有限。
目的:提供关于多发性骨软骨瘤自然史的有价值信息,为治疗建议提供信息,并预防骨软骨瘤引起的损伤。
设计:这项对多发性骨软骨瘤患儿的回顾性队列研究包括从首次随访到最后一次随访的纵向数据,患者人口统计学信息为 12 个月,疾病演变数据为 36 个月以上。
地点:数据来自多发性骨软骨瘤登记处,该登记处包括了 2003 年至 2017 年在博洛尼亚的意大利矫形研究所 Rizzoli 骨科研究所接受治疗的约 1200 名多发性骨软骨瘤患者的数据。
参与者:≤18 岁的多发性骨软骨瘤患者,提供了书面知情同意书,并至少有 1 次 12 个月以上的随访。
主要结果和测量:评估了人口统计学、临床表现、手术发生率和疾病演变(进展或消退)。结果采用描述性统计、新临床特征和手术的年度发生率以及 Kaplan-Meier 估计进行总结。根据意大利生长图表评估患者的身高。
结果:共有 158 名患者纳入这些分析。在整个随访过程中,80.4%的患者出现新的骨软骨瘤,57.6%出现新的畸形,23.4%出现新的功能受限。28.5%的患者在第 12 个月时出现新的骨软骨瘤,39.9%的患者在第 24 个月时出现新的骨软骨瘤,50%的患者在第 36 个月时出现新的骨软骨瘤。大多数新的骨软骨瘤出现在年轻人群中;0-4 岁的患者在 12、24 和 36 个月的随访中出现了更多的病变。在 12 个月内出现≥1 种新畸形的患者总体发生率为 17.7%,随着年龄的增长发生率逐渐降低(p=0.023)。此外,身高分析表明,13 岁是身高生长缓慢的一个转折点(p<0.0005)。在最后一次随访时,46.2%的患者疾病进展,而自发性和手术性消退分别占 7.6%(p=0.007)。
结论和相关性:这项自然史研究报告了多发性骨软骨瘤患者在骨骼发育过程中主要的一组临床相关数据,为患者管理和治疗干预措施的发展提供了见解。